Healthcare - Biotechnology - NYSE - US
$ 2.63
-8.36 %
$ 885 M
Market Cap
-1.21
P/E
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer.[ Read More ]
The intrinsic value of one NUVB stock under the base case scenario is HIDDEN Compared to the current market price of 2.63 USD, Nuvation Bio Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart NUVB
FINANCIALS
0
REVENUE
-99.8 M
OPERATING INCOME
-75.8 M
NET INCOME
-68 M
OPERATING CASH FLOW
8.92 M
INVESTING CASH FLOW
628 K
FINANCING CASH FLOW
727 K
REVENUE
-48.1 M
OPERATING INCOME
-41.2 M
NET INCOME
53 M
OPERATING CASH FLOW
29.1 M
INVESTING CASH FLOW
-1.54 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Nuvation Bio Inc.
| Current Assets | 616 M |
| Cash & Short-Term Investments | 611 M |
| Receivables | 3.7 M |
| Other Current Assets | 1.52 M |
| Non-Current Assets | 5.05 M |
| Long-Term Investments | 0 |
| PP&E | 4.32 M |
| Other Non-Current Assets | 728 K |
| Current Liabilities | 14 M |
| Accounts Payable | 2.21 M |
| Short-Term Debt | 3.94 M |
| Other Current Liabilities | 7.82 M |
| Non-Current Liabilities | 2.39 M |
| Long-Term Debt | 2.04 M |
| Other Non-Current Liabilities | 353 K |
EFFICIENCY
Earnings Waterfall
Nuvation Bio Inc.
| Revenue | 0 |
| Cost Of Revenue | 222 K |
| Gross Profit | -222 K |
| Operating Expenses | 99.8 M |
| Operating Income | -99.8 M |
| Other Expenses | -24 M |
| Net Income | -75.8 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-12.53%
ROE
-12.20%
ROA
-16.44%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nuvation Bio Inc.
| Net Income | -75.8 M |
| Depreciation & Amortization | 222 K |
| Capital Expenditures | -69 K |
| Stock-Based Compensation | 19.5 M |
| Change in Working Capital | 540 K |
| Others | -12 M |
| Free Cash Flow | -68.1 M |
Wall Street Analysts Price Targets
Nuvation Bio Inc.
Wall Street analysts predict an average 1-year price target for NUVB of $7 , with forecasts ranging from a low of $5 to a high of $10 .
NUVB Lowest Price Target
Wall Street Target
5 USD
90.11%
NUVB Average Price Target
Wall Street Target
7 USD
166.16%
NUVB Highest Price Target
Wall Street Target
10 USD
280.23%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Nuvation Bio Inc.
Sold
0-3 MONTHS
163 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
220 K USD 1
0-3 MONTHS
2.82 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
6 days ago
Nov 11, 2024
|
Sell 163 K USD
|
Wang Junyuan Jerry
CEO, ANHEART THERAPEUTICS LTD. |
- 56361
|
2.89 USD |
|
1 month ago
Oct 08, 2024
|
Bought 220 K USD
|
Mashal Robert
Director |
+ 99981
|
2.2 USD |
|
1 month ago
Oct 08, 2024
|
Bought 41.7 USD
|
Mashal Robert
Director |
+ 19
|
2.195 USD |
|
4 months ago
Jun 25, 2024
|
Bought 825 K USD
|
Cui Xiangmin
Director |
+ 277895
|
2.97 USD |
|
4 months ago
Jun 24, 2024
|
Bought 1 M USD
|
Cui Xiangmin
Director |
+ 336874
|
2.98 USD |
|
4 months ago
Jun 21, 2024
|
Bought 226 K USD
|
Cui Xiangmin
Director |
+ 75411
|
3 USD |
|
4 months ago
Jun 20, 2024
|
Bought 262 K USD
|
Cui Xiangmin
Director |
+ 87715
|
2.99 USD |
|
5 months ago
Jun 11, 2024
|
Bought 500 K USD
|
BLICKENSTAFF KIM D
Director |
+ 172189
|
2.9043 USD |
|
1 year ago
Sep 21, 2023
|
Bought 72.1 K USD
|
NODELMAN OLEG
Director |
+ 53000
|
1.3611 USD |
|
1 year ago
Sep 20, 2023
|
Bought 159 K USD
|
NODELMAN OLEG
Director |
+ 117100
|
1.362 USD |
|
1 year ago
Sep 19, 2023
|
Bought 6.46 M USD
|
NODELMAN OLEG
Director |
+ 5143000
|
1.2562 USD |
|
1 year ago
Feb 21, 2023
|
Bought 72.1 K USD
|
NODELMAN OLEG
Director |
+ 53000
|
1.3611 USD |
|
1 year ago
Feb 20, 2023
|
Bought 159 K USD
|
NODELMAN OLEG
Director |
+ 117100
|
1.362 USD |
|
1 year ago
Feb 19, 2023
|
Bought 6.46 M USD
|
NODELMAN OLEG
Director |
+ 5143000
|
1.2562 USD |
|
1 year ago
Dec 05, 2022
|
Bought 84 K USD
|
FALBERG KATHRYN E
Director |
+ 43000
|
1.9526 USD |
|
1 year ago
Dec 02, 2022
|
Bought 93.2 K USD
|
FALBERG KATHRYN E
Director |
+ 47000
|
1.9827 USD |
|
1 year ago
Dec 01, 2022
|
Bought 168 K USD
|
FALBERG KATHRYN E
Director |
+ 84959
|
1.9727 USD |
|
1 year ago
Nov 30, 2022
|
Bought 139 K USD
|
FALBERG KATHRYN E
Director |
+ 75041
|
1.8535 USD |
|
2 years ago
Apr 05, 2022
|
Sell 14 M USD
|
Omega Fund V GP Manager, Ltd.
director: |
- 2500000
|
5.6 USD |
|
2 years ago
Apr 05, 2022
|
Sell 14 M USD
|
Omega Fund V, L.P.
10 percent owner |
- 2500000
|
5.6 USD |
|
2 years ago
Dec 15, 2021
|
Sell 5.04 M USD
|
Omega Fund V, L.P.
10 percent owner |
- 500000
|
10.07 USD |
|
2 years ago
Dec 07, 2021
|
Sell 13.7 M USD
|
Omega Fund V, L.P.
10 percent owner |
- 1400000
|
9.8 USD |
|
2 years ago
Nov 24, 2021
|
Bought 1.25 M USD
|
NODELMAN OLEG
Director |
+ 163268
|
7.6859 USD |
|
3 years ago
Jul 31, 2021
|
Bought 489 K USD
|
NODELMAN OLEG
Director |
+ 56598
|
8.64 USD |
|
3 years ago
Mar 31, 2021
|
Bought 1.58 M USD
|
NODELMAN OLEG
Director |
+ 151544
|
10.45 USD |
|
2 years ago
Nov 24, 2021
|
Bought 167 K USD
|
NODELMAN OLEG
Director |
+ 21758
|
7.6859 USD |
|
3 years ago
Jul 31, 2021
|
Sell 489 K USD
|
NODELMAN OLEG
Director |
- 56598
|
8.64 USD |
|
3 years ago
Mar 31, 2021
|
Sell 1.58 M USD
|
NODELMAN OLEG
Director |
- 151544
|
10.45 USD |
|
2 years ago
Nov 22, 2021
|
Sell 2.88 M USD
|
Omega Fund V, L.P.
10 percent owner |
- 295000
|
9.76 USD |
|
2 years ago
Nov 23, 2021
|
Sell 351 USD
|
Omega Fund V, L.P.
10 percent owner |
- 36
|
9.75 USD |
|
3 years ago
Nov 03, 2021
|
Sell 18.5 M USD
|
Omega Fund V, L.P.
10 percent owner |
- 2000000
|
9.25 USD |
|
3 years ago
Oct 28, 2021
|
Sell 9.74 M USD
|
Omega Fund V, L.P.
10 percent owner |
- 1015000
|
9.6 USD |
|
3 years ago
Oct 29, 2021
|
Sell 417 K USD
|
Omega Fund V, L.P.
10 percent owner |
- 45000
|
9.27 USD |
|
3 years ago
Apr 13, 2021
|
Bought 283 K USD
|
NODELMAN OLEG
Director |
+ 27534
|
10.271 USD |
|
3 years ago
Apr 12, 2021
|
Bought 1.1 M USD
|
NODELMAN OLEG
Director |
+ 116255
|
9.4878 USD |
|
3 years ago
Apr 09, 2021
|
Bought 2.63 M USD
|
NODELMAN OLEG
Director |
+ 262230
|
10.0306 USD |
|
3 years ago
Apr 13, 2021
|
Bought 40.7 K USD
|
NODELMAN OLEG
Director |
+ 3966
|
10.271 USD |
|
3 years ago
Apr 12, 2021
|
Bought 159 K USD
|
NODELMAN OLEG
Director |
+ 16745
|
9.4878 USD |
|
3 years ago
Apr 09, 2021
|
Bought 379 K USD
|
NODELMAN OLEG
Director |
+ 37770
|
10.0306 USD |
|
3 years ago
Mar 30, 2021
|
Bought 49.9 K USD
|
Bazemore Robert B
Director |
+ 5000
|
9.9799 USD |
|
4 years ago
Jul 06, 2020
|
Bought 3.9 M USD
|
EcoR1 Panacea Holdings, LLC
director, 10 percent owner: |
+ 390000
|
10 USD |
7. News
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw.
businesswire.com
- 1 month ago
Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster presentation on September 14, 2024, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
businesswire.com
- 2 months ago
Nuvation Bio to Present at the Cantor Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Cantor Global Healthcare Conference in New York, NY on Thursday, September 19, 2024, at 9:45 a.m. E.T. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.
businesswire.com
- 2 months ago
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced multiple updates for its taletrectinib program. Data from the global, pivotal Phase 2 TRUST-II study has been accepted for an oral presentation at WCLC 2024 taking place September 7-10 in San Diego, California. Pooled data from both pivotal Phase 2 studies, TRUST-I and TRUST-II, has been accepted for a poster pr.
businesswire.com
- 3 months ago
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Data were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib.
prnewswire.com
- 5 months ago
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
SAN FRANCISCO, U.S. and SUZHOU, China , June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Data were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib.
prnewswire.com
- 5 months ago
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, its investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clini.
businesswire.com
- 5 months ago
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in a hybrid presentation at the Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 5, 2024, at 1:30 p.m. ET. A live webcast.
businesswire.com
- 5 months ago
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the first quarter ended March 31, 2024, and provided a business update. “The first quarter of 2024 included multiple significant events for Nuvation Bio. We announced and subsequently completed the acquisition of AnHeart Therapeutics, whic.
businesswire.com
- 6 months ago
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I clinical study (NCT04395677) evaluating taletrectinib in patients in China with ROS1-positive non-small cell lung cancer (NSCLC) will be reported in an oral presentation at the 2024 American Society of Clinical Oncolo.
businesswire.com
- 6 months ago
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of the acquisition of AnHeart Therapeutics Ltd. (AnHeart), a late-stage, global biopharmaceutical company developing novel precision therapies for people with cancer. With the acquisition's completion, AnHeart is now a wholly-owned subsidiary of.
businesswire.com
- 7 months ago
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Nuvation Bio has acquired an advanced pipeline candidate, taletrectinib, leading to a surge in market cap approaching $1 billion. Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation. Nuvation Bio also now has other pipeline candidates, including safusidenib and NUV-868, and has sufficient liquid assets to fund operations for years without help.
seekingalpha.com
- 7 months ago
8. Profile Summary
Nuvation Bio Inc. NUVB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 885 M
Dividend Yield
0.00%
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Contact
1500 Broadway, New York, NY, 10036
https://www.nuvationbio.com
IPO Date
Aug. 26, 2020
Employees
203
Officers
Mr. Moses Makunje CPA
Vice President of Finance and Principal Accounting & Financial Officer
Dr. David Liu M.D., Ph.D.
Chief Medical Officer
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Dr. David C. Hanley Ph.D.
Chief Technical Operations Officer
Ms. Stacy Markel
Chief People Officer
Ms. Colleen Sjogren
Chief Commercial Officer
Dr. David T. Hung M.D.
Founder, President, Chief Executive Officer & Chairman
Mr. Philippe Sauvage
Chief Financial Officer & Principal Financial Officer
Stephen Dang
Vice President of Legal & Secretary
Dr. Gary Hattersley Ph.D.
Chief Scientific Officer